Cargando…
The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
BACKGROUND: Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK. This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality five common chronic diseases (chronic obstructive pulmonary disease (COP...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490740/ https://www.ncbi.nlm.nih.gov/pubmed/22935195 http://dx.doi.org/10.1186/1471-2458-12-712 |
_version_ | 1782248861656416256 |
---|---|
author | Sheng, Xia Murphy, Michael J MacDonald, Thomas M Wei, Li |
author_facet | Sheng, Xia Murphy, Michael J MacDonald, Thomas M Wei, Li |
author_sort | Sheng, Xia |
collection | PubMed |
description | BACKGROUND: Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK. This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality five common chronic diseases (chronic obstructive pulmonary disease (COPD), osteoarthritis (OA), rheumatoid arthritis (RA), chronic kidney disease (CKD), and diabetes mellitus (DM)) and to compare effectiveness with the rest of the population not recorded as having these diseases. METHODS: A population-based cohort study was conducted in Tayside population who had at least two TC measurements between 1993 and 2007. There were 12,140 patients with chronic diseases and 9,481 patients in the rest of the population not recorded as having these chronic diseases. The main outcomes were TC change from baseline, CV events and all-cause mortality. RESULTS: Statin-associated TC reductions varied from 15% to 28% with baseline value of between 5.1 and 5.9 mmol/L in the primary prevention (PP) and from 7% to 23% with baseline value of 4.5 to 5.2 mmol/L in the secondary prevention (SP) among chronic diseases patients. In the rest of the population, TC reductions with statins were 31% in PP and 28% in SP with baselines of 6.3 mmol/L and 5.3 mmol/L, respectively (test of heterogeneity with chronic disease groups: p < 0.001). A notional reduction of 0.5 mmol/L in TC predicted variable reductions in incident CV events of 30% in RA, 19% in CKD, and 20% in DM, and recurrent CV events by 62% in COPD, 16% in CKD, and 19% in DM. The corresponding figures for the rest of population were 12% for incident CV events and 17% for the recurrent CV events, respectively. Risk reductions for all-cause mortality varied from 20% to 36% in PP and from 18% to 40% in SP, except in OA or RA patients in the chronic diseases and 11% in PP and 16% in the rest of population (test of heterogeneity: p > 0.05). CONCLUSIONS: The effectiveness of statins in common chronic diseases varied. With the exception of diabetes, statins tends to be less effective in patients with the chronic diseases compared with the rest of the study population. Changes in TC with statins appear not to correlate well with the changes in cardiovascular events and all-cause mortality. |
format | Online Article Text |
id | pubmed-3490740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34907402012-11-07 The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population Sheng, Xia Murphy, Michael J MacDonald, Thomas M Wei, Li BMC Public Health Research Article BACKGROUND: Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK. This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality five common chronic diseases (chronic obstructive pulmonary disease (COPD), osteoarthritis (OA), rheumatoid arthritis (RA), chronic kidney disease (CKD), and diabetes mellitus (DM)) and to compare effectiveness with the rest of the population not recorded as having these diseases. METHODS: A population-based cohort study was conducted in Tayside population who had at least two TC measurements between 1993 and 2007. There were 12,140 patients with chronic diseases and 9,481 patients in the rest of the population not recorded as having these chronic diseases. The main outcomes were TC change from baseline, CV events and all-cause mortality. RESULTS: Statin-associated TC reductions varied from 15% to 28% with baseline value of between 5.1 and 5.9 mmol/L in the primary prevention (PP) and from 7% to 23% with baseline value of 4.5 to 5.2 mmol/L in the secondary prevention (SP) among chronic diseases patients. In the rest of the population, TC reductions with statins were 31% in PP and 28% in SP with baselines of 6.3 mmol/L and 5.3 mmol/L, respectively (test of heterogeneity with chronic disease groups: p < 0.001). A notional reduction of 0.5 mmol/L in TC predicted variable reductions in incident CV events of 30% in RA, 19% in CKD, and 20% in DM, and recurrent CV events by 62% in COPD, 16% in CKD, and 19% in DM. The corresponding figures for the rest of population were 12% for incident CV events and 17% for the recurrent CV events, respectively. Risk reductions for all-cause mortality varied from 20% to 36% in PP and from 18% to 40% in SP, except in OA or RA patients in the chronic diseases and 11% in PP and 16% in the rest of population (test of heterogeneity: p > 0.05). CONCLUSIONS: The effectiveness of statins in common chronic diseases varied. With the exception of diabetes, statins tends to be less effective in patients with the chronic diseases compared with the rest of the study population. Changes in TC with statins appear not to correlate well with the changes in cardiovascular events and all-cause mortality. BioMed Central 2012-08-30 /pmc/articles/PMC3490740/ /pubmed/22935195 http://dx.doi.org/10.1186/1471-2458-12-712 Text en Copyright ©2012 Sheng et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sheng, Xia Murphy, Michael J MacDonald, Thomas M Wei, Li The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population |
title | The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population |
title_full | The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population |
title_fullStr | The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population |
title_full_unstemmed | The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population |
title_short | The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population |
title_sort | comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490740/ https://www.ncbi.nlm.nih.gov/pubmed/22935195 http://dx.doi.org/10.1186/1471-2458-12-712 |
work_keys_str_mv | AT shengxia thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation AT murphymichaelj thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation AT macdonaldthomasm thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation AT weili thecomparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation AT shengxia comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation AT murphymichaelj comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation AT macdonaldthomasm comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation AT weili comparativeeffectivenessofstatintherapyinselectedchronicdiseasescomparedwiththeremainingpopulation |